Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis

Jae Seok Roe; Chang Il Hwang; Tim D.D. Somerville; Joseph P. Milazzo; Eun Jung Lee; Brandon Da Silva; Laura Maiorino; Hervé Tiriac; C. Megan Young; Koji Miyabayashi; Dea Filippini; Brianna Creighton; Richard A. Burkhart; Jonathan M. Buscaglia; Edward Kim; Jean L. Grem; Audrey J. Lazenby; James A. Grunkemeyer; Michael A. Hollingsworth; Paul M. Grandgenett; Mikala Egeblad; Youngkyu Park; David A. Tuveson; Christopher R. Vakoc

doi:10.1016/j.cell.2017.07.007

Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis

Jae Seok Roe, Chang Il Hwang, Tim D.D. Somerville, Joseph P. Milazzo, Eun Jung Lee, Brandon Da Silva, Laura Maiorino, Hervé Tiriac, C. Megan Young, Koji Miyabayashi, Dea Filippini, Brianna Creighton, Richard A. Burkhart, Jonathan M. Buscaglia, Edward Kim, Jean L. Grem, Audrey J. Lazenby, James A. Grunkemeyer, Michael A. Hollingsworth, Paul M. GrandgenettMikala Egeblad, Youngkyu Park, David A. Tuveson, Christopher R. Vakoc

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

127 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancies, owing in part to its propensity for metastasis. Here, we used an organoid culture system to investigate how transcription and the enhancer landscape become altered during discrete stages of disease progression in a PDA mouse model. This approach revealed that the metastatic transition is accompanied by massive and recurrent alterations in enhancer activity. We implicate the pioneer factor FOXA1 as a driver of enhancer activation in this system, a mechanism that renders PDA cells more invasive and less anchorage-dependent for growth in vitro, as well as more metastatic in vivo. In this context, FOXA1-dependent enhancer reprogramming activates a transcriptional program of embryonic foregut endoderm. Collectively, our study implicates enhancer reprogramming, FOXA1 upregulation, and a retrograde developmental transition in PDA metastasis.

Original language	English (US)
Pages (from-to)	875-888.e20
Journal	Cell
Volume	170
Issue number	5
DOIs	https://doi.org/10.1016/j.cell.2017.07.007
State	Published - Aug 24 2017

Keywords

enhancer
FOXA1
metastasis
organoid
pancreatic cancer
pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/j.cell.2017.07.007

Fingerprint Dive into the research topics of 'Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis'. Together they form a unique fingerprint.

Cite this

Roe, J. S., Hwang, C. I., Somerville, T. D. D., Milazzo, J. P., Lee, E. J., Da Silva, B., Maiorino, L., Tiriac, H., Young, C. M., Miyabayashi, K., Filippini, D., Creighton, B., Burkhart, R. A., Buscaglia, J. M., Kim, E., Grem, J. L., Lazenby, A. J., Grunkemeyer, J. A., Hollingsworth, M. A., ... Vakoc, C. R. (2017). Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell, 170(5), 875-888.e20. https://doi.org/10.1016/j.cell.2017.07.007

Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. / Roe, Jae Seok; Hwang, Chang Il; Somerville, Tim D.D.; Milazzo, Joseph P.; Lee, Eun Jung; Da Silva, Brandon; Maiorino, Laura; Tiriac, Hervé; Young, C. Megan; Miyabayashi, Koji; Filippini, Dea; Creighton, Brianna; Burkhart, Richard A.; Buscaglia, Jonathan M.; Kim, Edward; Grem, Jean L.; Lazenby, Audrey J.; Grunkemeyer, James A.; Hollingsworth, Michael A.; Grandgenett, Paul M.; Egeblad, Mikala; Park, Youngkyu; Tuveson, David A.; Vakoc, Christopher R.

In: Cell, Vol. 170, No. 5, 24.08.2017, p. 875-888.e20.

Research output: Contribution to journal › Article › peer-review

Roe, JS, Hwang, CI, Somerville, TDD, Milazzo, JP, Lee, EJ, Da Silva, B, Maiorino, L, Tiriac, H, Young, CM, Miyabayashi, K, Filippini, D, Creighton, B, Burkhart, RA, Buscaglia, JM, Kim, E, Grem, JL, Lazenby, AJ, Grunkemeyer, JA, Hollingsworth, MA, Grandgenett, PM, Egeblad, M, Park, Y, Tuveson, DA & Vakoc, CR 2017, 'Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis', Cell, vol. 170, no. 5, pp. 875-888.e20. https://doi.org/10.1016/j.cell.2017.07.007

Roe, Jae Seok ; Hwang, Chang Il ; Somerville, Tim D.D. ; Milazzo, Joseph P. ; Lee, Eun Jung ; Da Silva, Brandon ; Maiorino, Laura ; Tiriac, Hervé ; Young, C. Megan ; Miyabayashi, Koji ; Filippini, Dea ; Creighton, Brianna ; Burkhart, Richard A. ; Buscaglia, Jonathan M. ; Kim, Edward ; Grem, Jean L. ; Lazenby, Audrey J. ; Grunkemeyer, James A. ; Hollingsworth, Michael A. ; Grandgenett, Paul M. ; Egeblad, Mikala ; Park, Youngkyu ; Tuveson, David A. ; Vakoc, Christopher R. / Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. In: Cell. 2017 ; Vol. 170, No. 5. pp. 875-888.e20.

@article{7c053b3ed694429388d05657b0beb360,

title = "Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis",

abstract = "Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancies, owing in part to its propensity for metastasis. Here, we used an organoid culture system to investigate how transcription and the enhancer landscape become altered during discrete stages of disease progression in a PDA mouse model. This approach revealed that the metastatic transition is accompanied by massive and recurrent alterations in enhancer activity. We implicate the pioneer factor FOXA1 as a driver of enhancer activation in this system, a mechanism that renders PDA cells more invasive and less anchorage-dependent for growth in vitro, as well as more metastatic in vivo. In this context, FOXA1-dependent enhancer reprogramming activates a transcriptional program of embryonic foregut endoderm. Collectively, our study implicates enhancer reprogramming, FOXA1 upregulation, and a retrograde developmental transition in PDA metastasis.",

keywords = "enhancer, FOXA1, metastasis, organoid, pancreatic cancer, pancreatic ductal adenocarcinoma",

author = "Roe, {Jae Seok} and Hwang, {Chang Il} and Somerville, {Tim D.D.} and Milazzo, {Joseph P.} and Lee, {Eun Jung} and {Da Silva}, Brandon and Laura Maiorino and Herv{\'e} Tiriac and Young, {C. Megan} and Koji Miyabayashi and Dea Filippini and Brianna Creighton and Burkhart, {Richard A.} and Buscaglia, {Jonathan M.} and Edward Kim and Grem, {Jean L.} and Lazenby, {Audrey J.} and Grunkemeyer, {James A.} and Hollingsworth, {Michael A.} and Grandgenett, {Paul M.} and Mikala Egeblad and Youngkyu Park and Tuveson, {David A.} and Vakoc, {Christopher R.}",

year = "2017",

month = aug,

day = "24",

doi = "10.1016/j.cell.2017.07.007",

language = "English (US)",

volume = "170",

pages = "875--888.e20",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis

AU - Roe, Jae Seok

AU - Hwang, Chang Il

AU - Somerville, Tim D.D.

AU - Milazzo, Joseph P.

AU - Lee, Eun Jung

AU - Da Silva, Brandon

AU - Maiorino, Laura

AU - Tiriac, Hervé

AU - Young, C. Megan

AU - Miyabayashi, Koji

AU - Filippini, Dea

AU - Creighton, Brianna

AU - Burkhart, Richard A.

AU - Buscaglia, Jonathan M.

AU - Kim, Edward

AU - Grem, Jean L.

AU - Lazenby, Audrey J.

AU - Grunkemeyer, James A.

AU - Hollingsworth, Michael A.

AU - Grandgenett, Paul M.

AU - Egeblad, Mikala

AU - Park, Youngkyu

AU - Tuveson, David A.

AU - Vakoc, Christopher R.

PY - 2017/8/24

Y1 - 2017/8/24

N2 - Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancies, owing in part to its propensity for metastasis. Here, we used an organoid culture system to investigate how transcription and the enhancer landscape become altered during discrete stages of disease progression in a PDA mouse model. This approach revealed that the metastatic transition is accompanied by massive and recurrent alterations in enhancer activity. We implicate the pioneer factor FOXA1 as a driver of enhancer activation in this system, a mechanism that renders PDA cells more invasive and less anchorage-dependent for growth in vitro, as well as more metastatic in vivo. In this context, FOXA1-dependent enhancer reprogramming activates a transcriptional program of embryonic foregut endoderm. Collectively, our study implicates enhancer reprogramming, FOXA1 upregulation, and a retrograde developmental transition in PDA metastasis.

AB - Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancies, owing in part to its propensity for metastasis. Here, we used an organoid culture system to investigate how transcription and the enhancer landscape become altered during discrete stages of disease progression in a PDA mouse model. This approach revealed that the metastatic transition is accompanied by massive and recurrent alterations in enhancer activity. We implicate the pioneer factor FOXA1 as a driver of enhancer activation in this system, a mechanism that renders PDA cells more invasive and less anchorage-dependent for growth in vitro, as well as more metastatic in vivo. In this context, FOXA1-dependent enhancer reprogramming activates a transcriptional program of embryonic foregut endoderm. Collectively, our study implicates enhancer reprogramming, FOXA1 upregulation, and a retrograde developmental transition in PDA metastasis.

KW - enhancer

KW - FOXA1

KW - metastasis

KW - organoid

KW - pancreatic cancer

KW - pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85026197846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026197846&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2017.07.007

DO - 10.1016/j.cell.2017.07.007

M3 - Article

C2 - 28757253

AN - SCOPUS:85026197846

VL - 170

SP - 875-888.e20

JO - Cell

JF - Cell

SN - 0092-8674

IS - 5

ER -